Article Text

Download PDFPDF

OP0130 Risk of cancer in patients with psoriasis/psoriatic arthritis: a population-based study in the province of british columbia
Free
  1. J.A Avina-Zubieta1,2,
  2. A. Dominique3,
  3. T.A. Simon3,
  4. H. Tavakoli1
  1. 1Arthritis Research Canada, Richmond
  2. 2Faculty of Medicine, University of British Columbia, Vancouver, Canada
  3. 3Bristol-Myers Squibb, Princeton, USA

Abstract

Background Psoriasis (PsO) is a relapsing chronic autoimmune disease of the skin. Up to one-third of patients (pts) also develop inflammatory arthritis, known as psoriatic arthritis (PsA). PsO/PsA, like other forms of chronic inflammatory arthritis, are often associated with complications such as cardiovascular disease and infections. However, data on the risk of cancer in pts with PsO/PsA at population level are limited.

Objectives To assess the risk of cancer in pts with newly diagnosed PsO/PsA at the population level.

Methods We created a population-based matched retrospective cohort of PsO/PsA pts diagnosed between 1 January 1997 and 31 December 2012 using administrative health data from British Columbia, Canada. We identified all incident cases of PsO/PsA and an equal number of controls matched on sex, age and calendar year. PsO/PsA cases met ≥1 of the following: 1 diagnostic code for PsO/PsA by a rheumatologist/dermatologist; ≥2 diagnostic codes for PsO/PsA, ≥2 months apart in a 2 year period by a non-rheumatologist/dermatologist; or ≥1 hospitalisation with diagnostic code for PsO/PsA. We evaluated incident cancers during follow-up from the Cancer Registry in both cohorts. Adjusted risk of cancers was estimated using a generalised estimating equation extension of multivariate Poisson regression models.

Results We identified 81 568 incident cases of PsO/PsA (mean age 48.5 years [SD 17.8], 51.5% female). Individuals with PsO/PsA were at significantly higher risk of being diagnosed with 8/41 types of cancer examined, including eye and orbit (4 fold), female genital (3 fold), non-melanoma skin (2 fold), prostate (males; 1.1 fold) (table 1). Incidence of rectal and colon cancer was lower among PsO/PsA pts relative to the non-PsO/PsA cohort (table 1).

Abstract OP0130 – Table 1

Incidence Rate (IR) and Incidence Rate Ratio (IRR) of Cancer Among PsO/PsA Pts Compared With the General Population

PY=patient years

Conclusions This general population-based study demonstrates that pts with PsO/PsA have an increased risk of several types of cancer, and a decreased risk of rectal and colon cancer. This association highlights the need to further explore potential risk factors and pathways that contribute to these complications.

Acknowledgements This study received an unrestricted grant from Bristol-Myers Squibb for an investigator-initiated project in PsO/PsA.

Disclosure of Interest J. A. Avina-Zubieta Grant/research support from: Bristol-Myers Squibb, A. Dominique Employee of: Bristol-Myers Squibb, T. Simon Employee of: Bristol-Myers Squibb, H. Tavakoli Grant/research support from: Bristol-Myers Squibb

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.